Department of Pediatrics, Shengjing Hospital of China Medical University, Shenyang, 110004, China.
Mol Med. 2022 Sep 6;28(1):107. doi: 10.1186/s10020-022-00536-y.
Necrotizing enterocolitis (NEC) is a devastating gastrointestinal disease that affects newborns, particularly preterm infants, and is associated with high morbidity and mortality. No effective therapeutic strategies to decrease the incidence and severity of NEC have been developed to date. Stem cell therapy has been explored and even applied in various diseases, including gastrointestinal disorders. Animal studies on stem cell therapy have made great progress, and the anti-inflammatory, anti-apoptotic, and intestinal barrier enhancing effects of stem cells may be protective against NEC clinically. In this review, we discuss the therapeutic mechanisms through which stem cells may function in the treatment of NEC.
新生儿坏死性小肠结肠炎（NEC）是一种严重的胃肠道疾病，影响新生儿，特别是早产儿，并与高发病率和死亡率相关。迄今为止，尚无有效的治疗策略来降低 NEC 的发生率和严重程度。干细胞治疗已经在各种疾病中进行了探索，甚至已经应用，包括胃肠道疾病。干细胞治疗的动物研究已经取得了很大的进展，干细胞的抗炎、抗凋亡和肠屏障增强作用可能对临床 NEC 具有保护作用。在这篇综述中，我们讨论了干细胞在治疗 NEC 中的作用机制。
